Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heamatology

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

European regulators give new medicines portal the go-ahead

EMA sets out plans for new online resource for patients, HCPs and academia 

Celgene building

Celgene bolsters blood cancer portfolio with $600m EngMab buy

Consolidates position as top company in current multiple myeloma market

- PMLiVE

Market access improvements in Turkey

With 78 million inhabitants, a universal public health insurance scheme, regulations largely harmonised with EU rules and a growing economy, Turkey - the largest market in the Middle East, North...

- PMLiVE

Surviving Brexit

How UK biopharma must adapt to a changing landscape

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

- PMLiVE

Combatting EU drug shortages

New guidelines to be issued after EMA report

- PMLiVE

Horizon swoops on Raptor to add rare disease products

Gains two new orphan medicines through the $800m deal

- PMLiVE

Newron back on track for Xadago approval in US

Italian firm is not required to conduct additional trials for its Parkinson’s disease drug

Brextinction

Evolution predicts tragic consequences from the UK's choice

- PMLiVE

Celgene disappointed as Revlimid fails lymphoma trial

Study shows improvement in progression-free survival but no overall survival rate benefit

EU flag

EU proposes reforms to make first-in-human trials safer

New guideline revision paper “takes into account lessons learnt” from fatal Bial trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links